מטפורמין טבע ®
teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.
מטפורמין טבע ®
teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.
מטפורמין טבע ®
teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.
יוקריאס 50/850 מ"ג
novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
אבנדמט 4 מ"ג/1000 מ"ג
glaxo smith kline (israel) ltd - metformin hydrochloride 1000 mg; rosiglitazone as maleate 4 mg - tablets - metformin and rosiglitazone - avandamet is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus : as dual combination therapy in patients who are already treated with combination rosiglitazone and metformin or who are not adequately controlled on metformin alone or in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea.
פרנדאז 50
bayer israel ltd - acarbose 50 mg - tablets - acarbose - treatment of niddm in patient's inadequatly controlled on diet alone or on diet and oral hypohlycaemia agents.
פרנדאז 100
bayer israel ltd - acarbose 100 mg - tablets - acarbose - treatment of niddm in patient's inadequatly controlled on diet alone or on diet and oral hypohlycaemia agents.
אקרוז 50
rafa laboratories ltd - acarbose - טבליה - acarbose 50 mg - acarbose - acarbose - treatment of non-insulin dependent diabetes mellitus (niddm) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.
אקרוז 100
rafa laboratories ltd - acarbose - טבליה - acarbose 100 mg - acarbose - acarbose - treatment of non-insulin dependent diabetes mellitus (niddm) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.
אקטוס 15 מג
tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 15 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi